Bevacizumab Improves Quality of Life in Patients with Recurrent Glioblastoma

Objective. To quantify the benefits in survival and quality of life in patients receiving bevacizumab (BEV) for recurrent glioblastoma (GBM). Methods. This is a retrospective study of 40 adult patients with recurrent GBM treated between 2005 and 2009 at a single institution. All patients had initial...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagpal, Seema, Harsh, Griffith, Recht, Lawrence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263615/
https://www.ncbi.nlm.nih.gov/pubmed/22312554
http://dx.doi.org/10.1155/2011/602812

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263615/
https://www.ncbi.nlm.nih.gov/pubmed/22312554
http://dx.doi.org/10.1155/2011/602812

Ejemplares similares